2026-04-14T02:11:52Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/137122025-10-24T10:43:20Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Johansson, Erin
author
ZIMNER RAPUCH, Sarah
author
Dimitriadis, Georgios K.
author
Bertrand, Marine
author
Curteis, Tristan
author
Ciudin Mihai, Andreea
2025-10-24T10:43:20Z
2025-10-24T10:43:20Z
2025-09-22T10:49:56Z2025-09-22T10:49:56Z2025-09
http://hdl.handle.net/11351/13712
Type 2 diabetes; Weight managementDiabetis tipus 2; Control del pesDiabetes tipo 2; Control de pesoAims
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Materials and Methods
Participants had body mass index (BMI) ≥ 27 kg/m2, with ≥1 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (HbA1c) 7%–10% on stable therapy. A heterogeneity assessment confirmed that study and patient baseline characteristics were similar. Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Results
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides. Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
Conclusions
In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide.Eli Lilly and Company
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Avaluació de resultats (Assistència sanitària)
Posologia
Obesitat - Tractament
Diabetis no-insulinodependent - Tractament
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Obesity Agents
Other subheadings::Other subheadings::Other subheadings::/administration & dosage
DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity
DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Overweight
DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2
Other subheadings::Other subheadings::Other subheadings::/drug therapy
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos antiobesidad
Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación
ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad
ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::sobrepeso
ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion